ACRIN and cancer imaging research have experienced groundbreaking developments within the last decade. We are grateful to have been instrumental in facilitating clinical research that is making a difference in the lives of cancer patients. Several ACRIN trials are now among the highest profile clinical trials in NCI’s portfolio and a majority of trials involve collaboration with therapy cooperative groups or industries.

Looking to future research plans, ACRIN anticipates developing even more precise quantitative approaches to diagnosis and image-guided therapy. Specific objectives involve surveillance of high-risk populations, administration of targeted therapies, and use of biomarkers to evaluate therapeutic response. The new Experimental Imaging Sciences Committee is charged with exploring new modalities, new uses for established modalities, and new equipment. I personally take great pride in the opportunity afforded me to work with so many talented imagers from across the country.

I invite you to explore our Web site to learn more about:

• How to participate in ACRIN trials and research activities
• The diversity of ACRIN’s research and related research strategies
• ACRIN’s extensive support for conducting multi-center trials.

We look forward to playing an active role in the innovations on the horizon for the cancer imaging research community.

Mitchell Schnall, MD, PhD
Network Chair